WeGuide lands A$1.9M to scale digital biomarker platform

WeGuide has secured A$1.9 million in CUREator+ funding to commercialise a platform for building regulatory-ready digital biomarkers faster and at lower cost. The Melbourne company is already working with NeuRA on a mobility recovery biomarker and says the funding will support product development, certification and expansion.

Why it matters: - Digital biomarker development is often slow, manual and expensive, which can delay precision medicine tools from reaching patients. - WeGuide’s platform aims to turn biomarker development into a standardized workflow, lowering the technical barrier for researchers and pharmaceutical companies. - Faster validation could help accelerate clinical adoption of multi-modal biomarkers across rehabilitation, research and drug development.

What happened: - WeGuide received A$1.9 million in CUREator+ funding in Melbourne. - The funding is aimed at commercialising a platform that streamlines digital biomarker development. - The company says the platform is designed to help researchers and pharmaceutical companies deliver regulatory-approved, multi-modal biomarkers faster and at lower cost than traditional methods. - WeGuide is building its first use case with Neuroscience Research Australia (NeuRA) to develop and validate a mobility recovery biomarker.

The details: - The platform covers the full workflow, from data fusion and study design to data collection, clinical validation and commercial deployment. - WeGuide says AI-powered agentic workflows automate data cleaning and generate algorithmic variants from multi-modal datasets. - The company says the process can cut work that normally takes months down to days. - The mobility study will recruit participants from rehabilitation settings. - The study will use wrist-worn wearables and patient-reported outcomes. - Results will be validated against the Short Physical Performance Battery, described as the gold standard for mobility assessment. - Professor Kim Delbaere, Senior Principal Research Scientist at NeuRA and Professor at UNSW Sydney, said a platform approach could help researchers bring biomarker ideas to life if it proves clinically valid. - WeGuide says it has partnerships with large contract research organisations serving pharmaceutical companies globally, plus major medical research centres and private clinics. - The company also points to Generation Victoria (GenV) as proof of scale. - GenV has recruited more than 120,000 families using WeGuide’s patient engagement platform. - WeGuide says the platform’s multicultural accessibility features supported data collection across that diverse cohort.

Between the lines: - The funding signals investor and grant-maker interest in infrastructure that can make precision medicine easier to deploy. - WeGuide is positioning itself less as a single biomarker vendor and more as a platform layer for repeated biomarker development. - The NeuRA project gives WeGuide a clinical proof point that could matter if the company wants broader adoption in regulated healthcare settings. - The comparison to cloud computing suggests WeGuide is betting that standardization will be the main unlock for the market.

What's next: - The CUREator+ funding will go toward product development, medical device certification and infrastructure expansion. - WeGuide says researchers will be able to keep full ownership of their biomarker algorithms while using the platform. - The company’s next milestone is demonstrating that the NeuRA collaboration can produce clinically validated digital biomarkers. - WeGuide says the funding will support its broader push to make precision medicine tools accessible globally.

The bottom line: - WeGuide now has capital, a clinical pilot and a large-scale deployment example to support its pitch that digital biomarker development can be standardized and commercialized.